Prodrug-type anticancer agent using cancer-specific enzymatic activity
[Problem] To provide a novel compound having great potential as a prodrug-type anticancer agent. [Solution] A compound represented by general formula (I) or a salt thereof.
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Europäisches Patentamt - (2024) vom: 21. März Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
URANO YASUTERU [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-03-21, Last update posted on www.tib.eu: 2024-04-03, Last updated: 2024-04-09 |
---|
Patentnummer: |
AU2019231422 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA000449792 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA000449792 | ||
003 | DE-627 | ||
005 | 20240409143051.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA000449792 | ||
035 | |a (EPA)AU2019231422 | ||
035 | |a (EPA)67847066 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a URANO YASUTERU |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prodrug-type anticancer agent using cancer-specific enzymatic activity |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2024-03-21, Last update posted on www.tib.eu: 2024-04-03, Last updated: 2024-04-09 | ||
520 | |a [Problem] To provide a novel compound having great potential as a prodrug-type anticancer agent. [Solution] A compound represented by general formula (I) or a salt thereof | ||
650 | 4 | |a C07F: Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium (metal-containing porphyrins c07d0487220000;macromolecular compounds c08) | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a C07H: Sugars; derivatives thereof; nucleosides; nucleotides; nucleic acids (derivatives of aldonic or saccharic acids c07c, c07d;aldonic acids, saccharic acids c07c0059105000, c07c0059285000;cyanohydrins c07c0255160000;glycals c07d;compounds of unknown constitution c07g;polysaccharides, derivatives thereof c08b;dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification c12n0015000000;sugar industry c13) | |
650 | 4 | |a C07C: Acyclic or carbocyclic compounds (macromolecular compounds c08;production of organic compounds by electrolysis or electrophoresis c25b0003000000, c25b0007000000) | |
650 | 4 | |a 615 | |
700 | 0 | |a KAMIYA MAKO |e verfasserin |4 aut | |
700 | 0 | |a HAYASHI KENTO |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 21. März |
773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/67847066/publication/AU2019231422A1?q=AU2019231422 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2024 |b 21 |c 03 |